First human trial shows promising results for IAVI’s Lassa Fever vaccine
Volunteers were monitored for 12 months post-vaccination, with immune responses activating both humoral and cellular immunity across all doses.
Volunteers were monitored for 12 months post-vaccination, with immune responses activating both humoral and cellular immunity across all doses.
All content is Copyrighted © 2025 The Premium Times, Nigeria